- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05438927
Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer
March 26, 2026 updated by: H. Lee Moffitt Cancer Center and Research Institute
The purpose of the study is to assess the feasibility and patient satisfaction with the Support through Remote Observation and Nutrition Guidance (STRONG) program.
The program provides nutrition and supportive care for participants living with pancreatic cancer who are receiving chemotherapy.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- ≥18 years old
- Newly diagnosed metastatic or newly recurrent pancreatic cancer or locally advanced pancreatic cancer
- Planning to initiate chemotherapy under the guidance of Moffitt
- Able to speak and read English or Spanish
- Able to provide informed consent
Exclusion Criteria:
- Documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g., psychosis, active substance abuse)
- Undergoing concurrent treatment for a second primary GI cancer
- ECOG status of 2 or greater
- Receipt of chemotherapy in the past 6 months for recurrent pancreatic cancer
- Use of parenteral or enteral nutrition
- Presence of malignant ascites
- The last two exclusion criteria were included because investigators do not anticipate that these patients would benefit from additional nutrition intervention.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Nutritional Support
Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth and remote monitoring through a smart phone app and wearable sensor to allow participants to log food intake while sharing data with a dietician
|
Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
Participants will receive individually tailored, biweekly nutrition counseling from a dietician via telehealth
Participants will take a survey at baseline and weeks 4,8,12 & 16.
The questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days.
This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much.
A higher total score indicates better quality of life.
Participants will take a survey at baseline and weeks 4,8,12 & 16.
The questionnaire measures participants anxiety with a scale of 0=not at all, 3=Nearly everyday.
Participants will take a survey at baseline and weeks 4,8,12 & 16.
The questionnaire measures participants depression with a scale of 0=not at all, 3=Nearly everyday.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment Rate - Feasibility
Time Frame: 12 Months
|
The study will be deemed feasible if ≥ 50% of eligible participants are recruited
|
12 Months
|
|
Data Collection - Feasibility
Time Frame: 12 Months
|
The study will be deemed feasible if ≥ 50% of participants submit study assessments
|
12 Months
|
|
Participant Rating on Ease of Use for the Mobile Application - Usability
Time Frame: 12 Months
|
The study will be deemed usable if ≥ 60% of participants rate the mobile application as easy-to-use for logging dietary intake
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participant Compliance with Palliative Care Visits - Intervention Adherence
Time Frame: 12 Months
|
Intervention adherence will be deemed successful if ≥ 60% of participants attend recommended palliative care visits (# of visits based on provider recommendation)
|
12 Months
|
|
Participant Compliance with Dietician Visits - Intervention Adherence
Time Frame: 12 Months
|
Intervention adherence will be deemed successful if ≥ 60% of participants meet with a dietician biweekly for 12 weeks
|
12 Months
|
|
Participant Compliance with Dietary Log - Intervention Adherence
Time Frame: 12 Months
|
Intervention adherence will be deemed successful if ≥ 60% of participants rack food intake for 8/12 weeks
|
12 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Pamela Hodul, MD, Moffitt Cancer Center
- Principal Investigator: Amir Alishahi Tabriz, MD, PhD, Moffitt Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 15, 2022
Primary Completion (Actual)
October 16, 2024
Study Completion (Actual)
September 30, 2025
Study Registration Dates
First Submitted
June 27, 2022
First Submitted That Met QC Criteria
June 27, 2022
First Posted (Actual)
June 30, 2022
Study Record Updates
Last Update Posted (Actual)
March 31, 2026
Last Update Submitted That Met QC Criteria
March 26, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Neoplasms by Site
- Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Behavioral Disciplines and Activities
- Psychological Tests
- Surveys and Questionnaires
- Patient Health Questionnaire
Other Study ID Numbers
- MCC-21795
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsUnited States, Japan, South Korea
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
The First Affiliated Hospital with Nanjing Medical...Peking University Cancer Hospital & InstituteNot yet recruiting
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of UtahNovartis Pharmaceuticals; Huntsman Cancer InstituteTerminatedMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingPancreatic Neoplasms | Pancreas Adenocarcinoma | Pancreatic Cancer Resectable | Cancer of Pancreas | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, AdultUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
Clinical Trials on Fitbit Data Collection
-
Tokyo UniversityGoogle LLC.CompletedCognitive Function | MCI | Cognition Disorders in Old Age | Frailty/SarcopeniaJapan
-
Care Management PlusCompletedHealth Information Technology | Nurse Based Care ManagementUnited States
-
NYU Langone HealthWithdrawnSevere Sleep Apnea | Severe Insomnia | Epileptiform ActivityUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingGastroEsophageal CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteUnited States Department of DefenseRecruitingPancreatic CancerUnited States
-
GCS Ramsay Santé pour l'Enseignement et la RechercheCompleted
-
M.D. Anderson Cancer CenterUnknownPediatric CancerUnited States
-
GlaxoSmithKlineCompletedInfections, StreptococcalRomania, Slovenia, Poland, Lithuania, Estonia
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker CochinCompleted
-
Hospices Civils de LyonCompleted